In this study, we utilized a combination of CRISPR-Cas9 genome ablation of TREM1 and its pharmacological inhibition by a novel small molecule inhibitor, VJDT, to characterize the impact of TREM1 silencing in cancer cells directly (9). Here, TREM1 is linked to cancer.